XML 78 R67.htm IDEA: XBRL DOCUMENT v3.24.3
Noncontrolling Interest (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 10, 2024
May 06, 2024
Mar. 13, 2024
Feb. 15, 2024
Jan. 26, 2024
Jan. 15, 2024
Mar. 07, 2023
Sep. 30, 2024
Sep. 30, 2023
Dec. 31, 2023
Noncontrolling Interest [Line Items]                    
Common stock shares outstanding               10,660,394   8,578,505
Issuance of shares, stated value               $ 0.001   $ 0.001
Gross proceeds               $ 29,798 $ 13,625  
Carrying value               $ 24,294    
Series A Convertible Preferred Stock [Member]                    
Noncontrolling Interest [Line Items]                    
Number of shares issued             13,625      
Issuance of shares, stated value             $ 1,000      
Preferred shares conversion price             $ 1.394      
Dividend percentage             20.00%      
Sale of stock, transaction value             $ 13,625      
Series A-1 Preferred Stock [Member]                    
Noncontrolling Interest [Line Items]                    
Number of shares issued     5,670              
Gross proceeds     $ 5,670              
Series B Convertible Preferred Stock [Member]                    
Noncontrolling Interest [Line Items]                    
Number of shares issued     44,285              
Issuance of shares, stated value               $ 0.001   $ 0.001
Dividend percentage               8.00%    
Conversion price     $ 1.2444              
Gross proceeds, sale of shares     $ 18,100              
Fair value of the consideration shares     31,790              
Carrying value     $ 24,294              
Fair value of deemed dividend     $ 7,500              
Lucid Series A and Lucid Series A-1 Preferred Stock [Member]                    
Noncontrolling Interest [Line Items]                    
Outstanding shares, percentage     100.00%              
Series B 1 Preferred Stock [Member]                    
Noncontrolling Interest [Line Items]                    
Number of shares issued   11,634                
Conversion price   $ 0.7228                
Gross proceeds, sale of shares   $ 11,600                
Lucid Diagnostics Inc [Member]                    
Noncontrolling Interest [Line Items]                    
Common stock shares issued               51,597,718    
Common stock shares outstanding               51,597,718    
Partners capital account units acquisitions               31,302,444    
Partners capital account units description On September 10, 2024, following preferred equity transactions completed by Lucid earlier in 2024 and the termination of voting proxies entered into between PAVmed and certain shareholders of Lucid, PAVmed’s voting interest in the Company was reduced to less than 50.0%, resulting in the loss of a controlling financial interest. However, PAVmed retains the ability to exercise significant influence over Lucid. Upon deconsolidation, the Company’s ownership of 31,302,444 shares of Lucid Diagnostics common stock was valued at $25.1 million, which resulted in a gain on deconsolidation of $72.3 million in the accompanying unaudited condensed consolidated statements of operations for the three and nine months ended September 30, 2024.                  
Received from payment of fees         $ 4,675          
Number of shares issued         3,331,771          
Common stock, dividends shares       3,331,747   38